摘要
目的探讨利培酮所致高催乳素血症的女性精神分裂症合并应用小剂量阿立哌唑的有效性和安全性。方法对38例利培酮所致高催乳素血症的女性精神分裂症患者,合并应用阿立哌唑5mg/d,分别于治疗前、治疗第4、8、12、24周末检测血清催乳素水平(PRL)、利培酮血浓度,并评定阳性与阴性症状量表(PANSS)。结果合并治疗4周后PRL显著下降[(67.58±49.12)ng/ml vs(36.18±35.32)ng/ml,P=0.000],在合并治疗的第8周末、第12周末PRL的下降仍存在统计学差异(P<0.05);而在第12周后PRL血浓度基本保持稳定(P>0.05)。8周末有效率达86.8%,24周末有效率81.6%。全部患者中,有5例在第24周末的PRL浓度较第12周末反跳性增高,其中2例患者再次超过正常范围。治疗前后PANSS评分无统计学差异(P>0.05)。结论合并小剂量阿立哌唑可在中短期内有效降低利培酮所致的高催乳素血症,不良反应少,但长期效果尚有待进一步观察。
Objective To study the safety and effectiveness of Aripiprazole in the treatment of hyperprolactinemia induced by Risperdal. Methods Totally 38 female patients with hyperprolactinemia induced by Risperdal received 5mg/d Aripiprazole combination treatment for 24 weeks. The serum prolactin （PRL）level, Risperdal blood concentration and PANSS were measured at baseline and at the end of 4^th, 8^th, 12^th ,24^th week respectively. Results After 4 weeks combination treatment, PRL level decreased significantly from 67.58±49. 12ng/ml to 36. 18±35.32ng/ml（P = 0. 000）. Compared with the baseline, PRL level also decreased significantly at the end of 8^th and 12^th month （P 〈 0.05）. The PRL level was stable after 12 weeks treatment. The effective rate was 86.8% and 81.6% respectively at the end of 12th and 24^th month. The PRL level of five patients rebounded at the end of 24^th month compared with that at the end of 12^th month, and two of those five patients＇ PRL level was higher than normal range. There were no significant differences in PANSS score at each viewpoint compared with the baseline （ P 〉 0.05 ）. Conclusion Aripiprazole is effective and safety in the short - and mid - term treatment of hyperprolactinemia induced by Risperdal, but the long - term effectiveness are not warranted.
出处
《精神医学杂志》
2011年第1期8-10,共3页
Journal of Psychiatry
基金
上海市交通大学医学院附属精神卫生中心院级课题(项目编号08-X-01)
